Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.

Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, Grandis JR.

Cancer Epidemiol. 2013 Aug;37(4):505-11. doi: 10.1016/j.canep.2013.02.009. Epub 2013 Mar 21.

2.

Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes.

Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M.

Head Neck. 2008 Sep;30(9):1139-47. doi: 10.1002/hed.20867.

3.

Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake.

Seibold P, Vrieling A, Heinz J, Obi N, Sinn HP, Flesch-Janys D, Chang-Claude J.

Cancer Epidemiol. 2014 Aug;38(4):419-26. doi: 10.1016/j.canep.2014.05.006. Epub 2014 Jun 17.

PMID:
24950597
4.

N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk.

Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM.

Carcinogenesis. 2001 Dec;22(12):1993-9.

PMID:
11751430
5.

Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.

Zenga J, Wilson M, Adkins DR, Gay HA, Haughey BH, Kallogjeri D, Michel LS, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B.

JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1118-27. doi: 10.1001/jamaoto.2015.0764.

PMID:
25902372
6.

Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.

Mota P, Silva HC, Soares MJ, Pego A, Loureiro M, Cordeiro CR, Regateiro FJ.

J Cancer Res Clin Oncol. 2015 May;141(5):851-60. doi: 10.1007/s00432-014-1868-z. Epub 2014 Nov 12.

PMID:
25388590
7.

Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors.

Rosenquist K, Wennerberg J, Annertz K, Schildt EB, Hansson BG, Bladström A, Andersson G.

Acta Otolaryngol. 2007 Sep;127(9):980-7.

PMID:
17712679
8.

Polymorphisms of glutathione S-transferase genes and survival of resected hepatocellular carcinoma patients.

Qu K, Liu SS, Wang ZX, Huang ZC, Liu SN, Chang HL, Xu XS, Lin T, Dong YF, Liu C.

World J Gastroenterol. 2015 Apr 14;21(14):4310-22. doi: 10.3748/wjg.v21.i14.4310.

9.

[Role of gene polymorphisms of phase II of xenobiotic biotransformation from glutathione-S-transferase and N-acetyltransferase families in susceptibility to lung cancer among Mayak workers].

Rusinova GG, Azizova TV, Viazovskaia NS, Glazkova IV, Gur'ianov MIu, Osovets SV.

Radiats Biol Radioecol. 2014 Jul-Aug;54(4):350-9. Russian.

PMID:
25775823
10.

Genetic polymorphisms of p53 and GSTP1,but not NAT2,are associated with susceptibility to squamous-cell carcinoma of the esophagus.

Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, Chen CJ, Hsieh CY, Wu MT.

Int J Cancer. 2000 Sep 20;89(5):458-64.

11.
12.

Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.

Okkels H, Sigsgaard T, Wolf H, Autrup H.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):225-31.

13.

Factors affecting swallow outcome following treatment for advanced oral and oropharyngeal malignancies.

Kalavrezos N, Cotrufo S, Govender R, Rogers P, Pirgousis P, Balasundram S, Lalabekyan B, Liew C.

Head Neck. 2014 Jan;36(1):47-54. doi: 10.1002/hed.23262. Epub 2013 Apr 4.

PMID:
23559533
14.

HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.

Perisanidis C, Savarese-Brenner B, Würger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M.

Oral Dis. 2013 Mar;19(2):206-11. doi: 10.1111/j.1601-0825.2012.01972.x. Epub 2012 Aug 14.

PMID:
22891969
15.

Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.

Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Mattson K, Vainio H.

J Natl Cancer Inst. 1996 Dec 18;88(24):1853-6.

PMID:
8961976
16.

Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y.

Am J Hematol. 2010 Jan;85(1):51-6. doi: 10.1002/ajh.21580.

17.

Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1,GSTT1, NAT1 and NAT2.

Godschalk RW, Dallinga JW, Wikman H, Risch A, Kleinjans JC, Bartsch H, Van Schooten FJ.

Pharmacogenetics. 2001 Jul;11(5):389-98.

PMID:
11470992
18.

Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.

Zgheib NK, Shamseddine AA, Geryess E, Tfayli A, Bazarbachi A, Salem Z, Shamseddine A, Taher A, El-Saghir NS.

Mutat Res. 2013 Jul-Aug;747-748:40-7. doi: 10.1016/j.mrfmmm.2013.04.004. Epub 2013 Apr 27.

PMID:
23628324
19.

Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms.

Potter JD, Bigler J, Fosdick L, Bostick RM, Kampman E, Chen C, Louis TA, Grambsch P.

Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):69-75.

20.

Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma.

Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, Miki H, Fujii T, Yoshino K, Kusuoka H, Monden M.

Int J Cancer. 1999 Mar 1;80(5):685-8.

Supplemental Content

Support Center